Payment overview · 2025
General Payments
$186.25
9 reported records · 5 companies
Healthcare provider profile · identity verified
Sam Alexander Samarrai, MD
Allopathic & Osteopathic Physicians|Family Medicine · TEMPLE, TX · NPI 1972000461
Verified facts
What the public records show
CMS Open Payments records show Sam Alexander Samarrai, MD received $186.25 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 42.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.76 | 42.8% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $40.12 | 21.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.88 | 17.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $18.25 | 9.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.24 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.25 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.36 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $40.12 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.40 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 383 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 222 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 63 |
| Lisinopril | Lisinopril | 208 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 44 |
| Losartan Potassium | Losartan Potassium | 139 | 47 |
| Gabapentin | Gabapentin | 134 | 39 |
| Metformin Hcl | Metformin Hcl | 118 | 43 |
| Omeprazole | Omeprazole | 107 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 30 |
| Furosemide | Furosemide | 89 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 32 |
| Eliquis | Apixaban | 81 | 26 |
| Ozempic | Semaglutide | 79 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 25 |
| Trazodone Hcl | Trazodone Hcl | 76 | 24 |
| Simvastatin | Simvastatin | 73 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 23 |
| Montelukast Sodium | Montelukast Sodium | 72 | 20 |
| Lorazepam | Lorazepam | 56 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 14 |
| Alprazolam | Alprazolam | 55 | 19 |
| Tramadol Hcl | Tramadol Hcl | 55 | 23 |
| Meloxicam | Meloxicam | 54 | 22 |
| Famotidine | Famotidine | 53 | 21 |
| Nifedipine Er | Nifedipine | 53 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 17 |
| Sertraline Hcl | Sertraline Hcl | 50 | 22 |
| Azithromycin | Azithromycin | 46 | 35 |
| Buspirone Hcl | Buspirone Hcl | 46 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 12 |
| Farxiga | Dapagliflozin Propanediol | 42 | 12 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 18 |
| Carvedilol | Carvedilol | 37 | 15 |
| Propranolol Hcl | Propranolol Hcl | 37 | 14 |
| Atenolol | Atenolol | 36 | 12 |
| Allopurinol | Allopurinol | 35 | 13 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 21 |
| Potassium Chloride | Potassium Chloride | 32 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 12 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | 12 |
| Testosterone | Testosterone | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Finasteride | Finasteride | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.25 · 9 records | ABBVIE INC. | AUSTEDO XR, INGREZZA, MOUNJARO, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error